Enavate's Zenas Pharma Footnote: Obexelimab Pipeline Watch
Inside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Spreadsheets are powerful tools for investment planning. Discover how to utilize them to track and manage your investments efficiently.
20,347 articlesInside ENAVATE's disclosed stake in Zenas BioPharma and why the Obexelimab pipeline is grabbing attention. Learn what...
Rising housing costs strain households and the broader economy. Smart tax policy can lower those costs by acceleratin...
Credit conditions are tightening ahead of any Fed move, driven by higher bond yields and a wave of AI financing. Inve...
Micron Technology posted a strong quarter but faced a sharp pullback as investors priced in a tougher near-term path....
Policy makers and tech leaders converge to treat China as a shared risk in AI leadership, signaling potential shifts ...
The iShares Core U.S. Aggregate Bond ETF (AGG) has produced a five-year price return near zero, even as it manages mo...
Red Cat Holdings posted a record Q4 revenue of $26.2 million and full-year $40.7 million, but margins stayed thin and...
Super Micro Computer posted a margin-led earnings surprise that beat expectations and lifted full-year guidance, prom...
A reality TV moment on a political landmark becomes a money lesson. This article breaks down pricing psychology, how ...
LifeStance Health Group stunned the market with a beat-and-raise quarter, sending its stock up roughly 20%. This deep...
Rocket Lab rockets higher after a record Q1 FY2026 showing strong revenue and a bloated backlog, signaling momentum f...
Wolfspeed has bounced on recent news, but deep profitability and liquidity issues linger. This guide breaks down the ...